FDA Approval Summary: Sunitinib for the Treatment of Progressive Well-Differentiated Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors

On May 20, 2011, the U.S. Food and Drug Administration (FDA) approved sunitinib malate capsules (Sutent®; Pfizer, Inc., New York) for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNETs) in patients with unresectable locally advanced or metastatic disease. In a...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Blumenthal, Gideon M., Cortazar, Patricia, Zhang, Jenny J., Tang, Shenghui, Sridhara, Rajeshwari, Murgo, Anthony, Justice, Robert, Pazdur, Richard
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: AlphaMed Press 2012
Pynciau:
Regulatory Issues: FDA
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3425529/
https://ncbi.nlm.nih.gov/pubmed/22836448
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0044
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg